Harnessing a Safe Novel Lipid Nanoparticle: Targeted Oral Delivery to Colonic Epithelial and Macrophage Cells in a Colitis Mouse Model
Open Access
- 9 November 2024
- journal article
- research article
- Published by MDPI AG in Nanomaterials
- Vol. 14 (22) , 1800
Abstract
A novel lipid nanoparticle (nLNP), formulated with three essential lipids to mimic ginger-derived exosomal particles, shows strong potential for delivering IL-22 mRNA specifically to the colon, presenting a unique oral drug delivery system for inflammatory bowel disease (IBD). However, its cellular targets and uptake behavior in healthy versus diseased colons remain unclear. Understanding these aspects is crucial for fully elucidating its targeting effectiveness in inflamed colon tissue. This study investigates the nLNP’s cellular targets in healthy and diseased mouse colons. Flow cytometry compared nLNP uptake in healthy mice and a DSS-induced acute colitis model. The results revealed efficient internalization of nLNP by colonic epithelial cells in healthy and inflamed mice. In non-inflamed mice, the small number of colonic macrophages resulted in minimal uptake of nLNP by these cells. In inflamed mice, macrophages migrated to the damaged epithelium, where nLNP uptake was significantly increased, highlighting the nLNP’s ability to target both epithelial and macrophage cells during inflammation. Additionally, safety assessments showed that the nLNP neither altered in vitro kinase activities nor exhibited immunotoxicity or induced in vivo toxicity at the maximum tolerated oral dose. These findings underscore the nLNP’s safety and potential as a promising epithelial/macrophage-targeted drug delivery platform for oral ulcerative colitis (UC) treatment.Keywords
Funding Information
- U.S. Department of Veterans Affairs (BX002526, BX004476, #709144, #833679)
- Crohn’s and Colitis Foundation of North America (BX002526, BX004476, #709144, #833679)
This publication has 41 references indexed in Scilit:
- Unleashing the Potential of Oral Deliverable Nanomedicine in the Treatment of Inflammatory Bowel DiseaseCellular and Molecular Gastroenterology and Hepatology, 2024
- Plant exosome-like nanovesicles derived from sesame leaves as carriers for luteolin delivery: Molecular docking, stability and bioactivityFood Chemistry, 2023
- Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the injured intestinal mucosa: A novel therapeutic solution to treat ulcerative colitisBiomaterials, 2022
- ‘Green’ nanotherapeutics from tea leaves for orally targeted prevention and alleviation of colon diseasesBiomaterials, 2021
- Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulationActa Pharmaceutica Sinica B, 2021
- Natural-lipid nanoparticle-based therapeutic approach to deliver 6-shogaol and its metabolites M2 and M13 to the colon to treat ulcerative colitisJournal of Controlled Release, 2020
- Macrophages: First Innate Immune Responders to Nanomaterials2020
- Safety screening in early drug discovery: An optimized assay panelJournal of Pharmacological and Toxicological Methods, 2019
- Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancerBiomaterials, 2016
- Risk of tuberculosis infection in anti-TNF-α biological therapy: From bench to bedsideJournal of Microbiology, Immunology and Infection, 2014